| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 75.1 | 94.8 | 89.1 |
| Other income | 2.0 | 0.2 | 2.3 |
| Total income | 77.2 | 95.0 | 91.5 |
| Profit before exceptional items & tax | 0.9 | 8.8 | 3.9 |
| Profit before tax | 0.9 | 8.8 | 3.9 |
| Net profit | 0.3 | 6.6 | 3.5 |
| Operating margin | 1.2% | 9.3% | 4.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -91.40% |
|---|---|
| Net profit, quarter on quarter | -95.50% |
| Revenue, year on year | -15.70% |
BSE results filing, NSE: HALEOSLABS. Figures extracted from the filing.
Haleos Labs Ltd: key numbers
- Share price
- ₹1,501.80
- Market cap
- ₹454.0 Cr
- Revenue (annual)
- ₹333.8 Cr
- Net profit (annual)
- ₹17.31 Cr
- P/E (TTM)
- 28.7×Sector 50.4×
- Promoter holding
- 72.11%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Haleos Labs Ltd
All →Haleos Labs Business Update
USFDA inspected the material subsidiary Mahi Drugs' API facility in Parawada. The inspection concluded with zero Form 483 observations.
Haleos Labs Other Announcement
Haleos Labs Ltd notified shareholders of the Annual Report and AGM notice weblink, while requesting updates to their KYC and email addresses.
Haleos Labs Annual Report
Haleos Labs Ltd has submitted its Annual Report for the financial year 2025-26, along with the Notice for its 20th Annual General Meeting.
Haleos Labs Dividend
Haleos Labs Limited recommended a final dividend of ₹15 per equity share for FY 2025-26. The record date is fixed for September 23, 2026.
Haleos Labs Q1 FY27 Results: Net Profit ₹1.8 Cr, Down 59.1% YoY
Haleos Labs Ltd reported revenue from operations of ₹72.9 Cr (-11.6% YoY) and net profit of ₹1.8 Cr (-59.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.8 Cr · -59.1% YoY